查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606343

肺癌診斷市場，診斷測試類型 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2024-2034 年

Lung Cancer Diagnostics Market, Diagnostic Test Type - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 228 Pages | 商品交期: 2-10個工作天內

價格

肺癌診斷市場 - 報告範圍

TMR 關於全球肺癌診斷市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2024 年至 2034 年預測期內市場指標的寶貴見解。市場，考慮2024年為基準年，2034年為預測年。該報告也提供了2024年至2034年全球肺癌診斷市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解肺癌診斷市場。

市場概況
2023年市場價值 151 億美元
2034 年市場價值 348 億美元
複合年成長率 7.9%

該報告深入探討了全球肺癌診斷市場的競爭格局。全球肺癌診斷市場的主要參與者已經確定，並且每位參與者都根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球肺癌診斷市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034 年全球市場分析與預測

第 5 章：關鍵見解

  • 業界最新技術進步
  • 關於液體活體組織切片作為肺癌診斷工具的出現的見解
  • 定價趨勢
  • 主要地區/國家的監管格局
  • 波特的五力分析
  • PESTEL分析
  • 價值鏈分析
  • 新進入者的市場策略
  • 最終用戶的關鍵購買指標
  • 關鍵產業事件（夥伴關係、協作、產品核准、併購、融資與投資）
  • 競爭對手提供的產品的基準化分析

第 6 章：全球市場分析與預測：依診斷測試類型

  • 簡介與定義
  • 主要發現/進展
  • 2020-2034 年診斷測試類型市場價值預測
    • 活體組織切片
      • 針吸切片
      • 經支氣管切片
      • 胸腔鏡切片
      • 液體活體組織切片
        • 循環腫瘤細胞 (CTC)
        • 循環腫瘤DNA
        • 無細胞 RNA (cfRNA)
        • 外泌體
        • 蛋白質體分析
      • 其他
    • 影像學檢查
      • 磁振造影 (MRI)
      • 電腦斷層掃描 (CT) 掃描
      • 胸部超音波檢查
      • 正子斷層掃描 (PET)
      • 其他影像學檢查
    • 分子檢測
    • 其他
  • 按診斷測試類型分類的市場吸引力

第 7 章：全球市場分析與預測：依產品類型

  • 簡介與定義
  • 主要發現/進展
  • 2020-2034年按產品類型分類的市場價值預測
    • 儀器儀表
    • 耗材
  • 按產品類型分類的市場吸引力

第 8 章：全球市場分析與預測：按癌症類型

  • 簡介與定義
  • 主要發現/進展
  • 2020-2034 年癌症類型市場價值預測
    • 非小細胞肺癌（NSCLC）
    • 小細胞肺癌（SCLC）
  • 按癌症類型分類的市場吸引力

第 9 章：全球市場分析與預測：按最終用戶

  • 簡介與定義
  • 主要發現/進展
  • 2020-2034 年最終用戶市場價值預測
    • 醫院
    • 診所
    • 診斷和影像中心
    • 癌症研究機構
  • 最終用戶的市場吸引力

第 10 章：全球市場分析與預測：按地區

  • 主要發現
  • 各地區市場價值預測
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 按地區分類的市場吸引力

第 11 章：北美市場分析與預測

  • 美國
  • 加拿大

第 12 章：歐洲市場分析與預測

  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區

第 13 章：亞太市場分析與預測

  • 中國
  • 日本
  • 印度
  • 澳洲和紐西蘭
  • 亞太地區其他地區

第 14 章：拉丁美洲市場分析與預測

  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區

第 15 章：中東和非洲市場分析與預測

  • 海灣合作理事會國家
  • 南非
  • 中東和非洲其他地區

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 公司市佔率分析 (2023)
  • 公司簡介
    • Abbott
    • Siemens Healthcare
    • GE Healthcare
    • Amoy Diagnostics Co.
    • Boditech Med, Inc.
    • Danaher
    • F. Hoffmann-La Roche
    • INOVIQ
    • MedGenome
    • Quest Diagnostics Incorporated
    • DiaSorin SpA
    • Oncocyte Corporation
    • QIAGEN
    • Thermo Fisher Scientific, Inc.
    • NanoString Technologies
    • Biodesix
    • Other Prominent Players
Product Code: TMRGL74159

Lung Cancer Diagnostics Market - Scope of Report

TMR's report on the global lung cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global lung cancer diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lung cancer diagnostics market.

Market Snapshot
Market Value in 2023US$ 15.1 Bn
Market Value in 2034US$ 34.8 Bn
CAGR7.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lung cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung cancer diagnostics market.

The report delves into the competitive landscape of the global lung cancer diagnostics market. Key players operating in the global lung cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lung cancer diagnostics market profiled in this report.

Key Questions Answered in Global lung cancer diagnostics Market Report:

  • What is the sales/revenue generated by lung cancer diagnostics across all regions during the forecast period?
  • What are the opportunities in the global lung cancer diagnostics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Lung Cancer Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global lung cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lung cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lung cancer diagnostics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Lung Cancer Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Lung Cancer Diagnostics Market Analysis and Forecasts, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Recent Technological Advancements in Lung Cancer Diagnostics Industry
  • 5.2. Insights on Emergence of Liquid Biopsy as a Lung Cancer Diagnostic Tool
  • 5.3. Lung Cancer Diagnostics Pricing Trends
  • 5.4. Regulatory Landscape across Key Regions / Countries
  • 5.5. PORTER's Five Forces Analysis
  • 5.6. PESTEL Analysis
  • 5.7. Value Chain Analysis
  • 5.8. Go-To Market Strategy for New Entrants
  • 5.9. Key Purchase Metrics for End-users
  • 5.10. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
  • 5.11. Benchmarking of the Products Offered by the Competitors

6. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Diagnostic Test Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 6.3.1. Biopsy
      • 6.3.1.1. Needle biopsy
      • 6.3.1.2. Transbronchial biopsy
      • 6.3.1.3. Thoracoscopic biopsy
      • 6.3.1.4. Liquid Biopsy
        • 6.3.1.4.1. Circulating Tumor Cells (CTCs)
        • 6.3.1.4.2. Circulating Tumor DNA
        • 6.3.1.4.3. Cell-Free RNA (cfRNA)
        • 6.3.1.4.4. Exosomes
        • 6.3.1.4.5. Proteomic Analysis
      • 6.3.1.5. Others
    • 6.3.2. Imaging Tests
      • 6.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.3.2.2. Computed Tomography (CT) Scan
      • 6.3.2.3. Chest Ultrasound
      • 6.3.2.4. Positron Emission Tomography (PET)
      • 6.3.2.5. Other Imaging Tests
    • 6.3.3. Molecular Testing
    • 6.3.4. Others
  • 6.4. Market Attractiveness By Diagnostic Test Type

7. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Product Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Product Type, 2020-2034
    • 7.3.1. Instruments
    • 7.3.2. Consumables
  • 7.4. Market Attractiveness By Product Type

8. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Cancer Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Cancer Type, 2020-2034
    • 8.3.1. Non-small cell lung cancer (NSCLC)
    • 8.3.2. Small cell lung cancer (SCLC)
  • 8.4. Market Attractiveness By Cancer Type

9. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By End-user, 2020-2034
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Diagnostic & Imaging Centers
    • 9.3.4. Cancer Research Institutes
  • 9.4. Market Attractiveness By End-user

10. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Region

11. North America Lung Cancer Diagnostics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 11.2.1. Biopsy
      • 11.2.1.1. Needle biopsy
      • 11.2.1.2. Transbronchial biopsy
      • 11.2.1.3. Thoracoscopic biopsy
      • 11.2.1.4. Liquid Biopsy
        • 11.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 11.2.1.4.2. Circulating Tumor DNA
        • 11.2.1.4.3. Cell-Free RNA (cfRNA)
        • 11.2.1.4.4. Exosomes
        • 11.2.1.4.5. Proteomic Analysis
      • 11.2.1.5. Others
    • 11.2.2. Imaging Tests
      • 11.2.2.1. Magnetic Resonance Imaging (MRI)
      • 11.2.2.2. Computed Tomography (CT) Scan
      • 11.2.2.3. Chest Ultrasound
      • 11.2.2.4. Positron Emission Tomography (PET)
      • 11.2.2.5. Other Imaging Tests
    • 11.2.3. Molecular Testing
    • 11.2.4. Others
  • 11.3. Market Value Forecast By Product Type, 2020-2034
    • 11.3.1. Instruments
    • 11.3.2. Consumables
  • 11.4. Market Value Forecast By Cancer Type, 2020-2034
    • 11.4.1. Non-small cell lung cancer (NSCLC)
    • 11.4.2. Small cell lung cancer (SCLC)
  • 11.5. Market Value Forecast By End-user, 2020-2034
    • 11.5.1. Hospitals
    • 11.5.2. Clinics
    • 11.5.3. Diagnostic & Imaging Centers
    • 11.5.4. Cancer Research Institutes
  • 11.6. Market Value Forecast By Country, 2020-2034
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Diagnostic Test Type
    • 11.7.2. By Product Type
    • 11.7.3. By Cancer Type
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Lung Cancer Diagnostics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 12.2.1. Biopsy
      • 12.2.1.1. Needle biopsy
      • 12.2.1.2. Transbronchial biopsy
      • 12.2.1.3. Thoracoscopic biopsy
      • 12.2.1.4. Liquid Biopsy
        • 12.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 12.2.1.4.2. Circulating Tumor DNA
        • 12.2.1.4.3. Cell-Free RNA (cfRNA)
        • 12.2.1.4.4. Exosomes
        • 12.2.1.4.5. Proteomic Analysis
      • 12.2.1.5. Others
    • 12.2.2. Imaging Tests
      • 12.2.2.1. Magnetic Resonance Imaging (MRI)
      • 12.2.2.2. Computed Tomography (CT) Scan
      • 12.2.2.3. Chest Ultrasound
      • 12.2.2.4. Positron Emission Tomography (PET)
      • 12.2.2.5. Other Imaging Tests
    • 12.2.3. Molecular Testing
    • 12.2.4. Others
  • 12.3. Market Value Forecast By Product Type, 2020-2034
    • 12.3.1. Instruments
    • 12.3.2. Consumables
  • 12.4. Market Value Forecast By Cancer Type, 2020-2034
    • 12.4.1. Non-small cell lung cancer (NSCLC)
    • 12.4.2. Small cell lung cancer (SCLC)
  • 12.5. Market Value Forecast By End-user, 2020-2034
    • 12.5.1. Hospitals
    • 12.5.2. Clinics
    • 12.5.3. Diagnostic & Imaging Centers
    • 12.5.4. Cancer Research Institutes
  • 12.6. Market Value Forecast By Country / Sub-region, 2020-2034
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Diagnostic Test Type
    • 12.7.2. By Product Type
    • 12.7.3. By Cancer Type
    • 12.7.4. By End-user
    • 12.7.5. By Country / Sub-region

13. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 13.2.1. Biopsy
      • 13.2.1.1. Needle biopsy
      • 13.2.1.2. Transbronchial biopsy
      • 13.2.1.3. Thoracoscopic biopsy
      • 13.2.1.4. Liquid Biopsy
        • 13.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 13.2.1.4.2. Circulating Tumor DNA
        • 13.2.1.4.3. Cell-Free RNA (cfRNA)
        • 13.2.1.4.4. Exosomes
        • 13.2.1.4.5. Proteomic Analysis
      • 13.2.1.5. Others
    • 13.2.2. Imaging Tests
      • 13.2.2.1. Magnetic Resonance Imaging (MRI)
      • 13.2.2.2. Computed Tomography (CT) Scan
      • 13.2.2.3. Chest Ultrasound
      • 13.2.2.4. Positron Emission Tomography (PET)
      • 13.2.2.5. Other Imaging Tests
    • 13.2.3. Molecular Testing
    • 13.2.4. Others
  • 13.3. Market Value Forecast By Product Type, 2020-2034
    • 13.3.1. Instruments
    • 13.3.2. Consumables
  • 13.4. Market Value Forecast By Cancer Type, 2020-2034
    • 13.4.1. Non-small cell lung cancer (NSCLC)
    • 13.4.2. Small cell lung cancer (SCLC)
  • 13.5. Market Value Forecast By End-user, 2020-2034
    • 13.5.1. Hospitals
    • 13.5.2. Clinics
    • 13.5.3. Diagnostic & Imaging Centers
    • 13.5.4. Cancer Research Institutes
  • 13.6. Market Value Forecast By Country / Sub-region, 2020-2034
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Diagnostic Test Type
    • 13.7.2. By Product Type
    • 13.7.3. By Cancer Type
    • 13.7.4. By End-user
    • 13.7.5. By Country / Sub-region

14. Latin America Lung Cancer Diagnostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 14.2.1. Biopsy
      • 14.2.1.1. Needle biopsy
      • 14.2.1.2. Transbronchial biopsy
      • 14.2.1.3. Thoracoscopic biopsy
      • 14.2.1.4. Liquid Biopsy
        • 14.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 14.2.1.4.2. Circulating Tumor DNA
        • 14.2.1.4.3. Cell-Free RNA (cfRNA)
        • 14.2.1.4.4. Exosomes
        • 14.2.1.4.5. Proteomic Analysis
      • 14.2.1.5. Others
    • 14.2.2. Imaging Tests
      • 14.2.2.1. Magnetic Resonance Imaging (MRI)
      • 14.2.2.2. Computed Tomography (CT) Scan
      • 14.2.2.3. Chest Ultrasound
      • 14.2.2.4. Positron Emission Tomography (PET)
      • 14.2.2.5. Other Imaging Tests
    • 14.2.3. Molecular Testing
    • 14.2.4. Others
  • 14.3. Market Value Forecast By Product Type, 2020-2034
    • 14.3.1. Instruments
    • 14.3.2. Consumables
  • 14.4. Market Value Forecast By Cancer Type, 2020-2034
    • 14.4.1. Non-small cell lung cancer (NSCLC)
    • 14.4.2. Small cell lung cancer (SCLC)
  • 14.5. Market Value Forecast By End-user, 2020-2034
    • 14.5.1. Hospitals
    • 14.5.2. Clinics
    • 14.5.3. Diagnostic & Imaging Centers
    • 14.5.4. Cancer Research Institutes
  • 14.6. Market Value Forecast By Country / Sub-region, 2020-2034
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Diagnostic Test Type
    • 14.7.2. By Product Type
    • 14.7.3. By Cancer Type
    • 14.7.4. By End-user
    • 14.7.5. By Country / Sub-region

15. Middle East & Africa Lung Cancer Diagnostics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 15.2.1. Biopsy
      • 15.2.1.1. Needle biopsy
      • 15.2.1.2. Transbronchial biopsy
      • 15.2.1.3. Thoracoscopic biopsy
      • 15.2.1.4. Liquid Biopsy
        • 15.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 15.2.1.4.2. Circulating Tumor DNA
        • 15.2.1.4.3. Cell-Free RNA (cfRNA)
        • 15.2.1.4.4. Exosomes
        • 15.2.1.4.5. Proteomic Analysis
      • 15.2.1.5. Others
    • 15.2.2. Imaging Tests
      • 15.2.2.1. Magnetic Resonance Imaging (MRI)
      • 15.2.2.2. Computed Tomography (CT) Scan
      • 15.2.2.3. Chest Ultrasound
      • 15.2.2.4. Positron Emission Tomography (PET)
      • 15.2.2.5. Other Imaging Tests
    • 15.2.3. Molecular Testing
    • 15.2.4. Others
  • 15.3. Market Value Forecast By Product Type, 2020-2034
    • 15.3.1. Instruments
    • 15.3.2. Consumables
  • 15.4. Market Value Forecast By Cancer Type, 2020-2034
    • 15.4.1. Non-small cell lung cancer (NSCLC)
    • 15.4.2. Small cell lung cancer (SCLC)
  • 15.5. Market Value Forecast By End-user, 2020-2034
    • 15.5.1. Hospitals
    • 15.5.2. Clinics
    • 15.5.3. Diagnostic & Imaging Centers
    • 15.5.4. Cancer Research Institutes
  • 15.6. Market Value Forecast By Country / Sub-region, 2020-2034
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Diagnostic Test Type
    • 15.7.2. By Product Type
    • 15.7.3. By Cancer Type
    • 15.7.4. By End-user
    • 15.7.5. By Country / Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Abbott
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Siemens Healthcare
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. GE Healthcare
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. Amoy Diagnostics Co.
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. Boditech Med, Inc.
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. Danaher
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. F. Hoffmann-La Roche
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. INOVIQ
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Product Portfolio
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. MedGenome
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Product Portfolio
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Quest Diagnostics Incorporated
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Product Portfolio
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
    • 16.3.11. DiaSorin S.p.A.
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Financial Overview
      • 16.3.11.3. Product Portfolio
      • 16.3.11.4. Business Strategies
      • 16.3.11.5. Recent Developments
    • 16.3.12. Oncocyte Corporation
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Financial Overview
      • 16.3.12.3. Product Portfolio
      • 16.3.12.4. Business Strategies
      • 16.3.12.5. Recent Developments
    • 16.3.13. QIAGEN
      • 16.3.13.1. Company Overview
      • 16.3.13.2. Financial Overview
      • 16.3.13.3. Product Portfolio
      • 16.3.13.4. Business Strategies
      • 16.3.13.5. Recent Developments
    • 16.3.14. Thermo Fisher Scientific, Inc.
      • 16.3.14.1. Company Overview
      • 16.3.14.2. Financial Overview
      • 16.3.14.3. Product Portfolio
      • 16.3.14.4. Business Strategies
      • 16.3.14.5. Recent Developments
    • 16.3.15. NanoString Technologies
      • 16.3.15.1. Company Overview
      • 16.3.15.2. Financial Overview
      • 16.3.15.3. Product Portfolio
      • 16.3.15.4. Business Strategies
      • 16.3.15.5. Recent Developments
    • 16.3.16. Biodesix
      • 16.3.16.1. Company Overview
      • 16.3.16.2. Financial Overview
      • 16.3.16.3. Product Portfolio
      • 16.3.16.4. Business Strategies
      • 16.3.16.5. Recent Developments
    • 16.3.17. Other Prominent Players
      • 16.3.17.1. Company Overview
      • 16.3.17.2. Financial Overview
      • 16.3.17.3. Product Portfolio
      • 16.3.17.4. Business Strategies
      • 16.3.17.5. Recent Developments

Lung Cancer Diagnostics Market

Lung Cancer Diagnostics Industry

Lung Cancer Diagnostics Market Size

Lung Cancer Diagnostics Market Share

Lung Cancer Diagnostics Market Growth

Lung Cancer Diagnostics Market Analysis

Lung Cancer Diagnostics Market Demand

Lung Cancer Diagnostics Market Forecast

Lung Cancer Diagnostics Market Trends

List of Tables

  • Table 01: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 02: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 03: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 04: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 05: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 06: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 07: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-users, 2020-2034
  • Table 08: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Region, 2020-2034
  • Table 09: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 10: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 11: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 12: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 13: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 14: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 15: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 16: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 17: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 19: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 20: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 21: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 22: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 23: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 24: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 25: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 26: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 27: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 28: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 29: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 30: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 31: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 32: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 33: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 34: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 35: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 36: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 37: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 38: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 39: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 40: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 41: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 42: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 43: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 44: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 45: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 46: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 47: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 48: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 02: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 03: Global Lung Cancer Diagnostics Market Share Analysis, by Diagnostic Test Type, 2023
  • Figure 04: Global Lung Cancer Diagnostics Market Share Analysis, by Diagnostic Test Type, 2034
  • Figure 05: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 06: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 07: Global Lung Cancer Diagnostics Market Share Analysis, by Product Type, 2023
  • Figure 08: Global Lung Cancer Diagnostics Market Share Analysis, by Product Type, 2034
  • Figure 09: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Type, 2024-2034
  • Figure 10: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 11: Global Lung Cancer Diagnostics Market Share Analysis, by Cancer Type, 2023
  • Figure 12: Global Lung Cancer Diagnostics Market Share Analysis, by Cancer Type, 2034
  • Figure 13: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 14: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 15: Global Lung Cancer Diagnostics Market Share Analysis, by End-user, 2023
  • Figure 16: Global Lung Cancer Diagnostics Market Share Analysis, by End-user, 2034
  • Figure 17: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 18: Global Lung Cancer Diagnostics Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 19: Global Lung Cancer Diagnostics Market Share Analysis, by Region, 2023
  • Figure 20: Global Lung Cancer Diagnostics Market Share Analysis, by Region, 2034
  • Figure 21: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Region, 2023-2034
  • Figure 22: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 23: North America Lung Cancer Diagnostics Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 24: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 25: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 26: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 27: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 28: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 29: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 30: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 31: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 32: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 34: Europe Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 35: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 36: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 37: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 38: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 39: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 40: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 41: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 42: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 43: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 45: Asia Pacific Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 46: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 48: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 49: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 50: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 51: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 52: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 53: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 54: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 55: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 56: Latin America Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 58: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 59: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 60: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 61: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 62: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 63: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 64: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 65: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 67: Middle East & Africa Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 68: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 69: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 70: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 71: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 72: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 73: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 74: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 75: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 76: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034